Pharmacological intervention of blood flow disturbances in diabetic retinal disease - Retinal blood flow and diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-001697-84-DK

Enrollment

Registered

2007-06-12

Start date

2008-08-24

Completion date

Unknown

Last updated

2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinal disease MedDRA version: 9.1 Level: LLT Classification code 10012661 Term: Diabetic eye disease

Interventions

Trade Name: Xalatan Pharmaceutical Form: Eye drops* INN or Proposed INN: LATANOPROST CAS Number: 130209824 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration num

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetes type 1 Blood pressure =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Persons treated with antiglaucoma medicine Persons with known eye disease, except diabetic retinal disease Persons with cardio-vascular disease or blood pressure >140/90. Pregnant women

Design outcomes

Primary

Measure	Time frame
Main Objective: The pharmacological influence of latanoprost, diclofenac and dorzolamide on retinal vessel diameters;Secondary Objective: ;Primary end point(s): To estimate changes, due to pharmalogical intervention, in retinal vessels	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026